secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029611
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated
-------------------------------------------------------------------------------

- Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).
- Reduced cortical/medullary tubular necrosis and neutrophilic inflammation at 0.35 mg/kg dose.
- Phase 1 clinical studies for Gemini initiated in February/March 2024.
- Data presented at the 29th Intl Conference on Advances in Critical Care Nephrology on March 12, 2024.
- Gemini is a synthetic TLR4 agonist that preconditions innate immunity to attenuate pro-inflammatory response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/0000950170-24-029611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/revb-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer